Pharmaceutical

No deadline set for policy; non-scheduled drugs account for 82% of market, average channel markup on common dosage forms is 43%

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving

USFDA has granted final approval to Zydus Lifesciences' generic version of IC-Green, an imaging agent used in vascular, transplant and cancer surgeries.

Strong custom synthesis growth, peptide opportunities and higher earnings estimates support Divi's outlook, but elevated valuations could restrict further stock upside

In the past month, Divi's Labs outperformed the market by soaring 25 per cent, as against a 1.2 per cent rise in the BSE Sensex.

Profit before tax rose 42.4 per cent to ₹769 crore as expenses grew slower than revenue and finance costs declined 35.6 per cent; tax expense more than doubled

The Swedish beauty brand will retain its commercial operations in India while entering a long-term manufacturing and supply partnership with Akums

Cadila Pharmaceuticals said Aciloc 150+ and Aciloc 300+ remain available without any restrictions on manufacture or sale, while reaffirming compliance with regulatory requirements

Restructuring positions biotech arm to focus on biologics and biosimilar

Biocon, Zydus, Dr Reddy's are among companies positioning for one of the largest biosimilar launches for cancer treatment

Indian drugmakers are reducing reliance on US generics, turning to specialty medicines, biosimilars and emerging markets to drive sustainable growth

Filed 10 applications with USFDA in FY26 to build a pipeline of differentiated products for regulated markets

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

The exemption, announced earlier this year, covers 40 petrochemical products used for making plastics and pharmaceuticals and is currently valid through June 30

In the past two months, the stock price of Panacea Biotec has skyrocketed 101 per cent.

Novo Nordisk plans to defend its obesity drug leadership in India as semaglutide patent expiry fuels competition from nearly 50 new market entrants

Uttar Pradesh plans an 8,000-acre healthcare manufacturing ecosystem to attract investments, boost exports and emerge as a major pharma hub

The drug regulator has asked central and state authorities to verify compliance with pharmacovigilance requirements during routine inspections and regulatory reviews

Spirulina can, indeed, prove a boon for a country like India where malnutrition, especially protein deficiency (anaemia), is rampant